MDIT Stock Overview
Medite Cancer Diagnostics, Inc. operates as a medical technology company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Medite Cancer Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.005 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -98.61% |
| 5 Year Change | -99.52% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| MDIT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | -3.2% |
| 1Y | n/a | -3.7% | 19.3% |
Return vs Industry: Insufficient data to determine how MDIT performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how MDIT performed against the US Market.
Price Volatility
| MDIT volatility | |
|---|---|
| MDIT Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MDIT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MDIT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | medite-group.com |
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning.
Medite Cancer Diagnostics, Inc. Fundamentals Summary
| MDIT fundamental statistics | |
|---|---|
| Market cap | US$8.58k |
| Earnings (TTM) | -US$5.42m |
| Revenue (TTM) | US$8.13m |
0.0x
P/S Ratio0.0x
P/E RatioIs MDIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDIT income statement (TTM) | |
|---|---|
| Revenue | US$8.13m |
| Cost of Revenue | US$6.21m |
| Gross Profit | US$1.93m |
| Other Expenses | US$7.35m |
| Earnings | -US$5.42m |
Last Reported Earnings
Sep 30, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MDIT perform over the long term?
See historical performance and comparison